Skip to main content

BioMensio mobile biosensing platform: the first truly palm-sized and accurate digital multi-drug test

Periodic Reporting for period 1 - BioMensio (BioMensio mobile biosensing platform: the first truly palm-sized and accurate digital multi-drug test)

Reporting period: 2019-03-01 to 2020-02-29

As the key to reducing drug related fatalities and injuries is using preventative tools more widely, the main goal of our project is to productise our platform so that it can be mass-deployed. The planned developments will turn our current prototype into a full drug testing device, which we plan to rapidly scale up for roadside, emergency medical care and workplace settings.
The Finnish Criminal Sanctions Agency, A-Clinic Foundation and Hospital District of Southwest Finland will be involved in the usability testing during our piloting phase.

The specific objectives of our Phase 2 project are the following:
- Adding 6 drug families for parallel detection (sufficient for road-side and workplace use).
- Improving analysis sensitivity and detection speed down to 1-2 minutes.
- Preparing for mass manufacturing by redesigning hardware components and readout algorithms, and implementing quality processes to reach €5/cartridge and €1,5/MSMA sensor COGS.
- Preparing for operational scalability by evaluating partners for long term cooperation.
- Validating the market readiness of our drug analyser by testing it with selected partners (Finnish Criminal Sanctions Agency, Police, A-Clinic Foundation, Hospital District of Southwest Finland).
- Conducting product demonstrations towards potential customers and new channel partners.
Work Package 1
Work has progressed nicely in WP1. All tasks started and have provided adequate results. Main achievements include that we are steadily approaching our performance targets and that we developed data-analysis scripts that are capable to automatically evaluate concentrations for up to 6 drugs from single saliva sample. In addition, we finalised work with saliva collection protocol and process.
Work will continue on during the second period, mainly work with cartridge v2.

Work Package 2
During the reporting period, we also achieved good results in WP2. We managed to improve several aspects of our hardware; mainly software and DAC curves readout and also improvement of the electronic read-out and hardware in general.
During the second project year, we will manufacture prototypes for piloting and improve the software and hardware performances based on pilot studies feedback. We will also test the overall manufacture chain.

Work Package 3
We started with preparation work in order for successful piloting next year. We established contacts with institute responsible for approval of drug testing devices for forensic market in Finland.
Next project year, we will carry out pilots (starting in August 2020).

Work Package 4
WP4 is an on-going work package. The work has progressed nicely: we have updated our website and LinkedIn page, participated at many fairs and conferences and established good contacts with key opinion leaders.
During the next project year, our main focus is further product demonstrations in fairs and congresses. In addition, IP issues (including FTO analysis) will be put into focus.

Work Package 5
We have carefully followed the work plan set out in the Biomensio proposal. In order to achieve the desired outcome, we made some changes in the work plan (concerning WP1). The amendment was approved and work is progressing nicely and with good results. All dissemination and commercialisation activities are on track and all the deliverables of the first period have been submitted.
To deploy drug testing as widely as detecting drunken drivers or employees, saliva-based solutions have a clear advantage. Saliva sample collection is quick and easy, non-gender specific, can be directly observed (no falsification), and can be done on-site with no need of special facilities. Advanced saliva testing technologies like ours can detect a person’s actual intoxication on the spot (not just prior consumption, which does not necessarily mean being under the influence at the time of taking the test). This is particularly relevant for traffic patrols, paramedics and workplaces.

Our Lab-on-a-Chip (LoaC) solution has several advantages to the commonly used solutions like Lateral Flow Test based methods. Our solution provides more rapid transport of sample liquid and reagents compared to LFT, and can therefore provide results faster and more reliably. Our solution is fully digital and connected to the Cloud offering workflow management benefits to the end user organization. We can provide also semi-quantitative or even quantitative results and we can upgrade the solution to handle the detection of more drugs than commonly available in the market.